First National Bank of Omaha’s Pacira BioSciences PCRX Stock Holding History

First National Bank of Omaha’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,608	Closed	-$218K	–	310
2024 Q2	$218K	Buy	+7,608	New	+$217K	0.01%	302
2024 Q1	–	Sell	-26,014	Closed	-$878K	–	337
2023 Q4	$878K	Buy	26,014 +2,604	+11%	+$76.2K	0.06%	224
2023 Q3	$718K	Sell	23,410 -1,327	-5%	-$47.8K	0.05%	239
2023 Q2	$991K	Buy	24,737 +142	+0.6%	+$5.87K	0.06%	221
2023 Q1	$1M	Buy	24,595 +254	+1%	+$10.1K	0.06%	218
2022 Q4	$940K	Sell	24,341 -800	-3%	-$38.9K	0.06%	224
2022 Q3	$1.34M	Buy	25,141 +188	+0.8%	+$10.5K	0.09%	204
2022 Q2	$1.45M	Sell	24,953 -187	-0.7%	-$12.2K	0.09%	198
2022 Q1	$1.92M	Buy	25,140 +1,688	+7%	+$113K	0.1%	187
2021 Q4	$1.41M	Buy	23,452 +414	+2%	+$22.8K	0.07%	202
2021 Q3	$1.29M	Buy	23,038 +14,308	+164%	+$825K	0.07%	213
2021 Q2	$612K	Hold	8,730	–	–	0.03%	267
2021 Q1	$612K	Sell	8,730 -1,052	-11%	-$75.1K	0.03%	267
2020 Q4	$585K	Buy	9,782 +947	+11%	+$55.5K	0.03%	269
2020 Q3	$531K	Buy	+8,835	New	+$513K	0.03%	251

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

First National Bank of Omaha's PCRX Position: Q3 2024 in Review

First National Bank of Omaha sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 7,608 shares — an estimated $218K sold.

First National Bank of Omaha first reported a position in PCRX in Q3 2020 and held it in 15 quarters. The position peaked at $1.92M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

First National Bank of Omaha reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
First National Bank of Omaha sold 7,608 Pacira BioSciences shares in Q3 2024, an estimated $218K.
First National Bank of Omaha first reported a position in Pacira BioSciences in Q3 2020 and held it in 15 quarters.
First National Bank of Omaha's Pacira BioSciences position peaked at $1.92M in Q1 2022.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on First National Bank of Omaha's 13F filing for Q3 2024, filed 15 Nov 2024.